Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).
Background: The three interferon beta preparations approved for treatment of relapsing-remitting multiple sclerosis (MS) differ in dose and frequency of administration. Interferon beta-1a 30 microg is administered once a week, interferon beta-1a 22 microg or 44 microg is given three times a week, an...
| Publicado en: | Lancet Vol. 359; no. 9316; pp. 1453 - 1461 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | clinical trial research randomized controlled trial Journal Article |
| Publicado: |
Lancet
4/27/2002
|
| Acceso en línea: | Ver este registro en EBSCOhost |